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SUMMARY
Most tumor cells take up more glucose than normal cells but metabolize glucose via glycolysis 
even in the presence of normal levels of oxygen, a phenomenon known as the Warburg effect. 
Tumor cells commonly express the embryonic M2 isoform of pyruvate kinase (PKM2) that may 
contribute to the metabolism shift from oxidative phosphorylation to aerobic glycolysis and 
tumorigenesis. Here we show that PKM2 is acetylated on lysine 305 and that this acetylation is 
stimulated by high glucose concentration. PKM2 K305 acetylation decreases PKM2 enzyme 
activity and promotes its lysosomal-dependent degradation via chaperone-mediated autophagy 
(CMA). Acetylation increases PKM2 interaction with HSC70, a chaperone for CMA, and 
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association with lysosomes. Ectopic expression of an acetylation mimetic K305Q mutant 
accumulates glycolytic intermediates and promotes cell proliferation and tumor growth. These 
results reveal an acetylation regulation of pyruvate kinase and the link between lysine acetylation 
and CMA.
INTRODUCTION
It was first noted by Otto Warburg that cancer cells rely mainly on aerobic glycolysis to 
generate ATP instead of more efficient mitochondrial oxidative phosphorylation, resulting in 
the increased rate of glucose uptake and lactate production even in the presence of sufficient 
oxygen supply (Warburg, 1956). Based on the dramatically increased glucose consumption 
in cancer cells, positron emission tomography (PET) of 2-(18F)-fluoro-2-deoxy-D-glucose 
(FDG) has been developed as a diagnostic technique to detect cancer cells in clinics (Funes 
et al., 2007). Activation of oncogenes or loss of tumor suppressor genes, such as mutations 
in Ras (Dang and Semenza, 1999; Ramanathan et al., 2005), AKT (Manning and Cantley, 
2007), Myc (Gordan et al., 2007a, 2007b), and p53 (Bensaad et al., 2006; Matoba et al., 
2006) increase glucose uptake and lactate production. These observations rekindle attention 
to Warburg effect and cancer metabolism.
A key glycolytic enzyme consistently altered in expression during tumorigenesis is pyruvate 
kinase (E.C. 2.7.1.40) (Altenberg and Greulich, 2004; Majumder et al., 2004), which 
catalyzes the transfer of phosphate from phosphoenolpyruvate (PEP) to ADP, resulting in the 
formation of pyruvate and ATP. There are four pyruvate kinase isoforms in mammals: L, R, 
M1, and M2. The L and R isoforms are specifically expressed in liver and red blood cells, 
respectively (Mazurek et al., 2005). PKM1 is expressed in most adult tissues, while PKM2 is 
exclusively expressed during embryonic development. Notably, most tumor cells re-express 
PKM2 (Dombrauckas et al., 2005; Mazurek et al., 2005), suggesting that the switch from 
PKM1 to PKM2 expression may be beneficial to tumor cells. Indeed, switching from PKM2 
to PKM1 reverses aerobic glycolysis, providing the selective growth advantage of PKM2 
expression for tumor cells in vivo (Christofk et al., 2008a). Recently, the PKM1-to-PKM2 
switch was found to be regulated by the Myc oncogene (David et al., 2009), providing 
further evidence linking the re-expression of the M2 isoform to the tumorigenesis.
The benefit of expressing PKM2 isoform to the rapidly growing embryonic and tumorigenic 
cells is believed to result from a decreased PK activity, which would lead to accumulation of 
various glycolytic metabolites for macromolecular biosynthesis to support cell growth. 
According to this notion, a regulation that decreases and increases PK activity could favor 
active dividing and quiescent cells, respectively. Unlike PKM1, full activity of PKM2 
requires allosteric activation by fructose 1, 6-bisphosphate (F-1, 6-BP). One such regulation 
is the binding of PKM2, but not PKM1, to phosphotyrosine, and this binding releases the 
allosteric activator F-1,6-BP from PKM2, leading to a decreased PKM2 activity and shifting 
catabolism from energy production to anabolic processes, leading to increased cell 
proliferation and tumor growth (Christofk et al., 2008b).
Protein acetylation has recently emerged as a broadly used modification in the regulation of 
a wide range of cellular processes (Choudhary et al., 2009; Kim et al., 2006; Zhao et al., 
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2010). In particular, we have found that most of the intermediate metabolic enzymes are 
acetylated and that acetylation can directly affect enzyme function (Zhao et al., 2010). 
Notably, acetylation of metabolic enzymes is regulated by extracellular cues, such as the 
nutrient availability. These findings indicate a broad role of acetylation in the coordination 
between the extracellular nutrients and intracellular metabolic pathways. In this paper, we 
report that PKM2 activity and protein stability are regulated by lysine acetylation. 
Specifically, acetylation of lysine K305 inhibits PKM2 activity and promotes lysosome-
dependent degradation of PKM2 via CMA. Our study reveals an acetylation regulation of 
pyruvate kinase and the link between acetylation and CMA.
RESULTS
PKM2 Is Acetylated at K305
Protein acetylation has long been known to play a key role in regulation of chromatin 
structure and gene transcription through modification of histones and nuclear transcription 
regulators (Soutoglou et al., 2000). We and others have recently discovered that a large 
number of nonnuclear proteins involved in a wide range of cellular pathways are also 
acetylated in human and mouse liver and leukemia cells (Choudhary et al., 2009; Kim et al., 
2006; Zhao et al., 2010). To further explore acetylation of nonnuclear protein in other 
tissues, we fractioned cell extracts of both human prostate cancer cell line LnCAP and 
cancer tissues into nuclear, mitochondrial, and cytosolic fractions. Cytosolic fractions were 
digested with trypsin, and acetylated peptides were immunoprecipitated with an antibody 
specific to acetyllysine. The immunopurified peptides were analyzed by tandem liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). These analyses identified 113 
acetylated proteins (data not shown), including several enzymes involved in glycolysis 
pathway. PKM2 was identified to be acetylated by the mass spectrometric analyses in 
samples from both cultured LnCAP cells and primary prostate cancer tissues. Identified 
acetylated PKM2 peptides are shown in Table S1, available online. To confirm its 
acetylation, Flag-tagged PKM2 was ectopically expressed into HEK293T cells and 
immunoprecipitated. Western blotting with anti-acetyllysine antibody confirmed that PKM2 
was indeed acetylated and its acetylation was enhanced approximately 3-fold after treatment 
with trichostatin A (TSA, an inhibitor of histone deacetylase HDAC I and II) (Ekwall et al., 
1997; Furumai et al., 2001) and nicotinamide (NAM, an inhibitor of the SIRT family 
deacetylases) (Avalos et al., 2005) (Figure 1A).
Two acetylation sites were identified in PKM2, K62 and K305 (Table S1). K62 is not 
conserved, while K305 is conserved from C. elegans to mammals (Figure S1A). We 
generated Gln and Arg substitution mutants of both sites (K62Q, K62R, K305Q, and 
K305R) and transfected 293T cells with these mutants individually, followed by direct 
western blotting with anti-acetyllysine antibody. Mutation of K62 only slightly reduced the 
acetylation of PKM2, while mutation of K305 reduced the PKM2 acetylation by 45% 
(Figure 1B), and double mutant of K62 and K305 comparably reduced PKM2 acetylation 
level as K305 single mutant (Figure S1B), indicating that under this condition K305 is a 
major acetylation site of ectopically expressed PKM2. There is still residual acetylation in 
the double mutants, suggesting additional acetylation sites in PKM2. To determine if K305 
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is acetylated in vivo, we generated antibody specific to acetylated K305. To characterize the 
specificity of this antibody, we performed dot blot assay and found that PKM2 acetyl K305 
antibody preferentially detected the acetylated peptide, but not the unmodified peptide 
(Figure S2A). Western blotting using this antibody detected strong signal of ectopically 
expressed wild-type PKM2, but not K305R mutant (Figure 1C). Moreover, PKM2 
knockdown significantly decreased the signal detected by the acetyl K305 antibody (Figure 
S2B). We also found that the antibody recognition of PKM2 was competed by acetylation-
modified peptide, but not by the unmodified peptide (Figure S2C), confirming the specificity 
of the antibody. Furthermore, western blotting of whole-cell extract from 293T cells detected 
a band that has a molecular weight of expected as PKM2 and whose intensity was 
substantially increased upon treatment of cells with TSA and NAM prior to the lysis (Figure 
1D). Similarly, NAM and TSA treatment also increased PKM2 acetylation in LnCAP cells 
(Figure S3A). As shown in Figure S1C, both NAM and TSA increased endogenous PKM2 
acetylation at K305. Moreover, IHC staining showed that PKM2 was indeed acetylated at 
K305 in human prostate cancer tissues (Figure S3B and Table S2). These results 
demonstrate an in vivo acetylation of PKM2 at Lys305.
Acetylation Mimetic Mutation at K305 Decreases PKM2 Activity
To determine the effect of acetylation at these two sites on PKM2 enzyme activity, we 
transfected 293T cells with individual PKM2 mutants and assayed for the PKM2 enzyme 
activity. Mutation of Lys62 to either Gln or Arg reduced the activity of PKM2 by 28% and 
40%, respectively, while mutation of Lys305 to Arg reduces the PKM2 activity by 29%. 
Notably, mutation of Lys305 by Gln, which may mimic acetyl modification (Chen et al., 
2008; Wang and Hayes, 2008; Zhang et al., 1998), dramatically decreased PKM2 activity by 
as much as 95% (Figure 1E). Furthermore, NAM and TSA treatment decreased PKM2 wild-
type but not mutant enzyme activity (Figure 1F). Kinetic analyses of recombinant PKM2 
proteins purified from E. coli revealed that the K305Q mutation reduced affinity toward its 
substrate PEP (Figure 1G). In contrast, the Km for ADP was not appreciably altered. 
Although the exact PEP concentration in prostate cancer cells is not known, the 
concentrations of PEP are reported to be between 4 and 140 μM in human and rat tissues 
(Liebermeister, 2005). These results suggest that the PKM2-K305Q would have a much 
lower activity under physiological PEP concentration, indicating an inhibitory role of K305 
acetylation in PKM2 regulation. Taken together with the findings that K305Q has a much 
more dramatic reduction than K62Q in catalytic activity, we therefore focus the study on the 
molecular mechanism and physiological function of K305 acetylation in PKM2 regulation.
Glucose Increases K305 Acetylation and Decreases PKM2 Protein Level
To determine if the K305 acetylation of PKM2 is dynamically regulated in vivo, we cultured 
293T cells with 25 mM glucose concentrations for different time points and examined the 
K305 acetylation. We found that K305 acetylation was increased in a time course-dependent 
manner (Figure 2A). More interestingly, the steady-state level of PKM2 decreased with the 
increase of PKM2 acetylation at K305 (Figure 2A). These results indicate a potential inverse 
correlation between PKM2 acetylation and protein levels in response to the change of 
glucose concentration.
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Acetyltransferase PCAF Promotes PKM2 Acetylation and Decreases PKM2 Protein Level
To identify the acetyltransferase responsible for PKM2 acetylation at K305, we examined 
four acetyltransferases, p300 (E1A binding protein, 300 Kda), CBP (CREB binding protein), 
PCAF (p300/CBP-associated factor, also known as K [lysine] acetyltransferase 2B, 
KAT2B), and GCN5 (KAT2A), and found that ectopically expressed PCAF bound to PKM2 
(Figure 2B) and dramatically increased PKM2 acetylation at K305 (Figure 2C), whereas the 
other acetyltransferases had little effect (data not shown). Consistent with a role in 
cytoplasm, a fraction of PCAF was found in the cytoplasm based on subcellular 
fractionation (Figures S4A and S4B). Notably, glucose significantly increased the interaction 
between PKM2 and PCAF (Figure 2D), while it only slightly increased PCAF protein level 
(Figure S4C). Knocking down PCAF significantly reduced K305 acetylation (Figure 2E), 
indicating that PCAF is a potential K305 acetyltransferase in vivo. To determine if PCAF 
could affect PKM2 enzyme activity, we analyzed the effect of ectopically expressing PCAF 
as well as PCAF knockdown on PKM2 enzyme activity. As expected, PCAF ectopic 
expression decreased PKM2 activity by 33%, while PCAF knockdown increased PKM2 
activity by 30% when the enzymatic activity was normalized against PKM2 protein (Figure 
2F). These data are consistent with a model that acetylation inhibits PKM2 activity. 
Moreover, ectopically expressing PCAF decreased the steady-state level of endogenous 
PKM2 (Figure 2G). To further test the role of acetylation, particularly K305 acetylation, in 
regulation of PKM2 protein levels, Flag-PKM2-WT, K305Q, and K305R mutant were stably 
expressed in HEK293 cells, and the cells were treated with TSA and NAM. Inhibition of 
deacetylases by TSA and NAM treatment decreased the level of PKM2 wild-type (Figure 
2H). In contrast, the same treatment had little effect on the protein levels of PKM2 K305Q 
and PKM2K305R, demonstrating that acetylation of K305 is important for PKM2 protein 
regulation (Figure 2H). Moreover, NAM and TSA treatment decreased the protein level of 
endogenous PKM2 but not PKM2K305R (Figure S4D). Together, our results indicate that 
PCAF decreases PKM2 protein level, possibly via acetylating PKM2 at K305.
Glucose-Induced PKM2 Degradation Requires CMA
The decrease of PKM2 protein level in cells grown in high glucose media led us to 
determine if it occurred at transcription level or protein stability. We found that the levels of 
PKM2 mRNA were moderately increased, but not decreased, with the increasing 
concentration of glucose (Figure 3A). Thus, the reduction of PKM2 protein by glucose is 
unlikely to be due to a transcriptional regulation. Similarly, inhibition of endogenous 
deacetylases by NAM and TSA treatment had no significant effect on PKM2 mRNA levels 
(Figure 3B). These results prompted us to test whether proteasome is involved in PKM2 
protein degradation. We treated 293T cells with a proteasome inhibitor MG132 and observed 
that it had no effect on the steady-state level of PKM2 (Figure 3C). In contrast, a similar 
MG132 treatment increased the level of phosphoenolpyruvate carboxykinase (PEPCK), a 
gluconeogenic enzyme known to be degraded by the proteasome pathway in response to 
high glucose (Zhao et al., 2010). This result indicates that high glucose-induced decrease of 
PKM2 is due neither to downregulation of PKM2 transcription nor to proteasome-dependent 
degradation.
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To elucidate the mechanism underlying PKM2 degradation, we considered the other major 
pathway of protein degradation, the lysosome system or autophagy. Three different 
autophagy mechanisms, macroautophagy, microautophagy, and chaperone-mediated 
autophagy (CMA), have been characterized. Both macroautophagy and microautophagy 
have the capacity to engulf large structures through both selective and nonselective 
mechanisms, whereas CMA degrades only soluble proteins, mostly in a selective manner 
(Mizushima et al., 2008). In CMA, heat shock protein Hsc70 binds to and recruits the target 
proteins to lysosomes through the lysosomal membrane receptor LAMP2A for degradation 
(Majeski and Dice, 2004).
We treated cells with Leupeptin, an inhibitor of lysosomal proteases (Jeong et al., 2009), and 
observed obvious accumulation of PKM2 protein and acetylation (Figure 3D) while 
treatment of cells with 6-aminonicotinamide, an ATP blocker and an activator of lysosomes 
(Yang et al., 2009), decreased PKM2 level (Figure 3E). Thus, these results indicate that 
lysosome is involved in high glucose-induced PKM2 degradation.
Prolonged serum deprivation can activate CMA (Cuervo et al., 1995; Wing et al., 1991). We 
therefore determined the effect of serum deprivation on the steady-state level of PKM2 and 
observed that serum starvation decreased PKM2 protein levels (Figure 3F), providing further 
support for a role of CMA in PKM2 degradation.
Both HSC70 and LAMP2A are critical components in the CMA pathway (Cuervo, 2009). To 
provide additional evidence to support the role of CMA in PKM2 degradation, we knocked 
down either HSC70 or LAMP2A and measured PKM2 protein levels. Knockdown of either 
HSC70 or LAMP2A significantly accumulated PKM2 (Figures 3G and 3H). Moreover, 
glucose-induced PKM2 degradation was blocked in LAMP2A knockdown cells (Figure 3I). 
We conclude that high glucose-induced PKM2 reduction is achieved through CMA-
mediated protein degradation.
PKM2 Acetylation Promotes Its Binding with HSC70 and Uptake by Lysosomes
The apparent inverse correlation between PKM2 acetylation and protein levels led us to 
explore a potential role of K305 acetylation in PKM2 degradation. In CMA, HSC70 
functions to recruit target proteins to lysosomes for degradation. We first employed acetyl 
mimetic mutant to examine if PKM2K305Q exhibits a binding with HSC70. 
Coimmunoprecipitation showed that K305Q mutant displayed a much stronger interaction 
with HSC70 than wild-type PKM2 (Figure 4A). Consistently, treatment of cells with 
deacetylase inhibitors TSA and NAM significantly increased the binding between PKM2 
and HSC70 (Figure 4B), suggesting that PKM2 acetylation may increase its interaction with 
HSC70. Furthermore, coexpression of HSC70 dramatically decreased the level of K305-
acetylated PKM2 (Figure 4C), consistent with a notion that HSC70 destabilizes the 
acetylated PKM2. The PKM2 immunoprecipitated by HSC70 had enriched K305-acetylated 
PKM2 (Figure 4D). The interaction between endogenous PKM2 and HSC70 was confirmed 
by coimmunoprecipitation (Figure 4E). These data demonstrate that HSC70 preferentially 
associates with the K305-acetylated PKM2. Importantly, the PKM2-HSC70 association was 
substantially increased with the increase of glucose concentrations (Figure 4F). Similarly, 
glucose treatment increased the interaction between endogenous PKM2 and HSC70 (Figure 
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S4E). These results indicate that K305 acetylation promotes PKM2 degradation by 
enhancing its interaction with HSC70 in response to glucose.
Proteins undergoing CMA-mediated lysosomal degradation often contain a loosely defined 
KFERQ motif important for HSC70 binding (Cuervo, 2009). The KFERQ motif usually 
contains five residues, including a critical glutamine (Q) residue that is preceded or followed 
by four amino acids consisting of a basic (R or K), an acidic (E or D), or a bulky 
hydrophobic residue (I, L, V, or F) (Dice, 1990). Inspection of PKM2 amino sequence 
reveals three potential HSC70 binding motifs, 184QVKQK188, 223EKDIQDLKF231, 
and 393QLFEE398. We replaced Q184V185, Q223D224, and Q393L394 by alanines and 
examined the interaction of each mutant with HSC70. While neither Q184A/V185A nor 
Q223A/D224A mutation decreased the interaction with HSC70, Q393A/L394A mutation 
significantly reduced its interaction with HSC70 (Figure 4G), providing an additional 
support for a CMA-mediated degradation of PKM2. Finally, gel filtration analysis showed 
that coexpression of PCAF led to a shift of a fraction of PKM2 to higher molecular complex 
and the acetylated PKM2 was exclusively present in the higher molecular weight fractions 
(Figure 4H). These observations are consistent with an idea that acetylation promotes the 
interaction of PKM2 and HSC70.
To determine if PKM2 can be uptaken by lysosomes, we incubated the immunopurified 
PKM2 with isolated lysosomes in vitro. The lysosomes were repurified and the associated 
PKM2 was detected by western blotting to determine PKM2 binding. When the above 
experiment was performed in the presence of lysosomal protease inhibitors, this assay would 
show the total PKM2 that was bound to and taken up by the lysososomes. We found that 
PKM2 bound to lysosomes. Moreover, the PKM2 isolated from TSA and NAM-treated cells 
showed more lysosomal binding and uptake (Figure 4I), suggesting that the acetylated 
PKM2 has higher affinity to lysosomes. Furthermore, the PKM2-Q393A/L394A mutant, 
which has mutations of the putative HSC70 recognition motif, significantly decreased 
lysosomal binding and uptake (Figure 4J). These results demonstrate that PKM2 can bind to 
and be uptaken by the lysosomes and that acetylation enhances these processes.
Acetylation Mimetic Mutant K305Q Accumulates Glycolytic Intermediates
Accumulation of glycolytic intermediates resulting from decreased PKM2 activity by 
cellular signals, such as binding with phosphotyrosine or phosphorylation by FGFR1 
(Christofk et al., 2008a; Hitosugi et al., 2009), has been suggested to promote cell and tumor 
growth. We wanted to determine the physiological function of PKM2 acetylation. To this 
end, we generated stable H1299 cell lines in which the endogenous PKM2 was knocked 
down by short hairpin RNA (shRNA) and either wild-type (referred to as H1299/PKM2), 
K305Q mutant (referred to as H1299/PKM2K305Q), or K305R mutant (referred to as H1299/
PKM2K305R) was stably expressed. Various glycolytic metabolites were measured by LC-
MS/MS analysis. We found that the H1299/PKM2K305Q cells accumulated more fructose-6-
phosphate (F-6P), glucose-6-phosphate (G-6P), and F-1,6-BP, but produced less lactate and 
pyruvate than H1299/PKM2 cells when these cells were cultured in the high glucose media 
(Figure 5A). The increase of F-6P, G-6P and F-1, 6-BP and decrease of lactate were 
statistically significant. In contrast, the H1299/PKM2K305R cells accumulated less F-6P and 
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G-6P, but produced more lactate than the H1299/PKM2 cells under the same culture 
conditions (Figure S5A). The decrease of F-6P and G-6P and increase of lactate were 
statistically significant. Interestingly, we found that the glycolysis rate in K305R cells was 
indeed higher compared to wild-type and K305Q cells, suggesting that acetylation inhibits 
PKM2, and thus accumulates glycolytic intermediates for biosynthesis (Figure S5B). 
Furthermore, we also observed a significant increase and decrease of NADPH in H1299 
cells expressing PKM2K305Q (Figure 5B) and PKM2K305R (Figure S5C), respectively. 
Together, these data show that expression of PKM2K305Q mutant accumulates glycolytic 
intermediates and NADPH.
PKM2 Mutant Promotes Cell Proliferation and Tumor Growth
Given the high frequency of PKM2 expression in tumor cells, we next examined the effect 
of mutation at K305 of PKM2 on cell proliferation and tumor growth. We first verified the 
knocking down of endogenous PKM2 and stable ectopic expression of both wild-type and 
K305Q mutant PKM2 (Figure 6A). We found that H1299/PKM2K305Q cells proliferated 
twice as fast as the H1299/PKM2 cells (Figure 6B), indicating a growth advantage conferred 
by the acetyl mimetic substitution at K305.
To determine whether PKM2K305Q mutant also rendered growth advantage to tumor cells in 
vivo, we performed xenograft studies. Three million H1299/PKM2 or H1299/PKM2K305Q 
cells were injected into nude mice, and tumor cell growth was monitored over a period of 
around 7 weeks. Sustained expression of Flag-tagged wild-type and K305Q mutant PKM2 
in xenograft tumors was verified by western blot analysis using the antibody specific to Flag 
and PKM2 (Figure 6A). As shown in Figure 6C, larger tumors were developed in mice 
injected with H1299/PKM2K305Q than in those injected with H1299/PKM2 cells. 
Measurement of the width of tumor demonstrates that H1299/PKM2K305Q cells give rise to 
significantly larger tumors than the H1299/PKM2 cells (Figure 6D). Taken together, these 
results suggested that substitution of K305 with an acetylation mimetic residue confers 
tumors cell growth advantage both in vitro and in vivo.
DISCUSSION
Metabolic alteration in cancer cells has emerged as an exciting topic in cancer research. It is 
particularly noteworthy that cancer cells display a robust increase in glucose uptake and a 
higher demand of metabolic intermediates for biosynthesis to support rapid cell growth. 
Among the glycolytic enzymes, pyruvate kinase is unique in that it shows a cancer-specific 
switch of expression from PKM1 to PKM2; the latter is normally reserved for expression in 
rapidly proliferating embryonic cells. We have observed that PKM2 is acetylated in cancer 
cells and that the K305 acetylation inhibits PKM2 by two mechanisms. Acetylation reduces 
enzymatic activity, likely due to its decreased affinity toward the substrate PEP, and 
destabilizes PKM2 via HCS70-mediated CMA.
The eukaryotic cell uses two main degradation systems, the proteasome and the lysosomes, 
to regulate protein stability (Ciechanover, 2005). The proteasome usually degrades short-
lived proteins, while the lysosome targets long-lived proteins. Among the three types of 
lysosome-dependent degradation (macroautophagy, microautophaqgy, and CMA), CMA is 
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unique that it shows a selective degradation of target proteins (Levine and Kroemer, 2007; 
Massey et al., 2004). The selectivity is achieved through the binding of HSC70 to a KFERQ-
like motif present in target proteins. It is estimated that approximately 30% of cytosolic 
soluble proteins contain KFERQ-like motifs (Dice et al., 1990), indicating a potential broad 
role of CMA in regulating protein stability.
A key step in CMA regulation is the interaction between chaperone and target proteins. For 
PKM2, it appears that acetylation plays a key role in regulating the interaction between 
HSC70 and PKM2. The acetylated PKM2 displays a stronger interaction with HSC70. For 
example, treatment with deacetylase inhibitors, NAM and TSA, significantly increases the 
interaction between HCS70 and PKM2. Moreover, HSC70 selectively coprecipitates the 
acetylated PKM2. Furthermore, acetylated PKM2 displays an enhanced interaction with 
lysosomes. Although the precise mechanism of acetylation in promoting the interaction 
between PKM2 and HSC70 is unclear, we have identified that the 393QLFEE398 is 
apparently essential for the interaction with HSC70. We speculate that acetylation of K305 
may cause conformational changes in PKM2, thus the 393QLFEE398 sequence in the 
acetylated PKM2 becomes accessible for recognition by HSC70. Our study provides the first 
example that acetylation regulates CMA by promoting the interaction between chaperone 
and target proteins.
Christofk et al. have suggested that PKM2 is important for cancer cell growth. A unique 
feature of the pyruvate kinase is that it acts at the end of the glycolytic pathway and that its 
product, pyruvate, can be metabolized into two major directions. Pyruvate can be reduced to 
produce lactate, which is often accumulated in cancer cells, or oxidized to acetyl-coA, which 
can be fed into the TCA cycle for energy production. An inhibition of pyruvate kinase will 
result in accumulation of glycolytic intermediates, which could be used for biosynthesis for 
cell growth, if glucose is available. In contrast, an inhibition of enzymes in earlier steps, 
such as hexokinase, would not accumulate glycolytic intermediates, thus the cell would not 
accumulate building materials for biosynthesis. This may potentially explain why cancer 
cells specifically express PKM2, which is activated by F-1, 6-BP and inhibited by tyrosine 
phosphorylated proteins (Christofk et al., 2008b; Mazurek et al., 2005). In this study, we 
present another mechanism of PKM2 inhibition by acetylation. We also demonstrate that 
expression of acetylation mimetic mutant PKM2 enhanced glycolytic intermediates and 
NADPH. As a result, the acetylation mimetic mutant PKM2 increases cell proliferation in 
vitro and tumor growth in vivo.
Glucose regulates PKM2 acetylation and protein levels. What is the physiological 
significance of this glucose-dependent regulation in cancer cells? PKM2, but not PKM1, has 
a low activity that can be activated allosterically by FBP (Jurica et al., 1998; Mazurek et al., 
2005). When glucose concentration is low, tumor cells would use the limited glucose for 
oxidative phosphorylation to generate energy for survival. So, under this condition, PKM2 is 
active due to activation by F-1, 6-BP and lacks acetylation-induced inhibition. When glucose 
concentration is high, tumor cells need to decrease PKM2 activity in order to accumulate 
glycolytic intermediates for cell growth. Although high glucose results in a high F-1, 6-BP, 
PKM2 activity is in check because high glucose induces PKM2 acetylation, which directly 
decreases PKM2 activity and indirectly stimulates the CMA-dependent degradation. 
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Therefore, together with activation by F-1, 6-BP, PKM2 regulation by glucose-induced 
acetylation would provide an advantage for tumor cell growth under glucose sufficiency. 
One may speculate that drugs modulating PKM2 activity or acetylation could have potential 
value for cancer treatment.
EXPERIMENTAL PROCEDURES
Cell Lysis and Immunological Procedures
Cells were lysed in a NP-40 buffer, and western blot analysis was carried out according to 
standard methods. Antibodies specific to Flag (Sigma), HSC70 (Abcam), Lamp2A (Abcam), 
HA (Santa Cruz), actin (Sigma), and PSA (Bio-world) were purchased commercially. 
Antibodies to pyruvate kinase and acetyl-PKM2(K305) were generated by immunizing 
rabbits with antigen peptides at Shanghai Genomic Inc.
Measurement of Pyruvate Kinase Activity
Pyruvate kinase activity was measured by a continuous assay coupled to lactate 
dehydrogenase (LDH). The change in absorbance resulting from NADH oxidation was 
measured using a F-4600 Fluorescence Spectrophotometer (HITACHI). Assays for PK 
activity were carried out as previously described (Christofk et al., 2008a).
Lysosome Binding and Uptake Assay
Lysosomes were isolated by following previously described procedures (Cuervo et al., 
1995). Both lysosome binding and uptake assays were carried out as described previously 
(Cuervo et al., 2004).
Short Hairpin RNA Constructs and Retroviral Production
A shRNA retrovirus targeting pyruvate kinase was constructed and retroviruses were 
produced using a two-plasmid packaging system as previously described (Christofk et al., 
2008a).
Putting Back
Flag-tagged human PKM2 and PKM2K305Q containing two silent nucleotide substitutions in 
the sequence corresponding to the shRNA-targeted region were cloned into the retroviral 
vector (pQCXIH) and were cotransfected into 293T cells together with vectors expressing 
the gag and vsvg genes. Retroviral supernatant was harvested 36 hr after initial plasmid 
transfection and mixed with polybrene (8 μg/ml) to increase the infection efficiency. H1299 
cells were infected with retrovirus and selected in hygromycin (350 μg/ml) for 2 weeks.
Cell Proliferation Analysis
3 × 104 cells were seeded in triplicate in 6-well plates, and cell numbers were counted every 
24 hr over a 5 day period.
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To extract metabolites, 2 × 107 cells was directly chilled into 2 ml ice-cold 80% ethanol 
containing 0.1% formic acid, followed by a centrifugation at 10,000 rpm for 20 min at 4°C. 
The supernatant was collected and dried in Concentrator 5301 (Eppendorf). The dried 
extract was dissolved in 200 μl 20% acetonitrile, and the insoluble material was removed by 
centrifugation (10,000 rpm for 20 min at 4 C). Of the supernatant, 20 μl was used to for LC-
MS analysis.
NADPH Assay
The assays were carried out according to the protocol of NADP/NADPH Assay Kit 
(BioVision).
Xenograft Studies
Nude mice (nu/nu, male 6- to 8-week-old) were injected subcutaneously with 3 × 106 H1299 
cells. Around 7 weeks after injection, the tumors were dissected and weighed.
Immunohistochemistry
Prostate samples were acquired from Affiliated Renji Hospital of Jiaotong University. A 
physician obtained informed consent from the patients. The procedures related to human 
subjects were approved by Ethic Committee of the Institutes of Biomedical Sciences (IBS), 
Fudan University. IHC was performed as previously described (Lei et al., 2006).
Measurement of Glycolysis Rate
Glycolysis rate was measured by monitoring the conversion of 5-3H-glucose to 3H2O, as 
described previously (Liang et al., 1997).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Acetylation at K305 Decreases PKM2 Enzyme Activity
(A) PKM2 is acetylated. Flag-PKM2 was transfected into 293T cells followed by treatment 
with TSA and NAM for the indicated time, and PKM2 acetylation and protein levels were 
analyzed by western blot with indicated antibody, respectively.
(B) Mutation of K305 decreases PKM2 acetylation. The indicated plasmids were 
cotransfected into 293T cells, and protein was immunoprecipitated (IP) for acetylation 
analysis. Acetylation levels were normalized against β-actin.
(C) Characterization of acetyl-PKM2 (K305) antibody. The indicated plasmids were 
transfected into 293T cells, and acetylation level of IPed Flag-PKM2 was measured by the 
site-specific K305 acetylation antibody.
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(D) Endogenous PKM2 is acetylated at K305. 293T cells were treated with TSA and NAM. 
Endogenous PKM2 was immunoprecipitated, and protein levels and acetylation of K305 
were determined by western blot with indicated antibodies (left panel). Relative PKM2 
K305 acetylation over protein level was quantified (right panel). Error bars represent ± SD 
for triplicate experiments.
(E) K305Q mutant decreases PKM2 enzyme activity. Flag-tagged wild-type and mutant 
PKM2 protein were expressed in 293T cells and purified by IP. The enzyme activity was 
measured and normalized against protein level. Mean values of relative enzyme activity of 
triplicate experiments with standard deviation (±SD) are presented.
(F) NAM and TSA treatment decreases PKM2 wild-type but not mutant enzyme activity. 
Flag-tagged wild-type and mutant PKM2 protein were expressed in 293T cells and treated 
with or without NAM and TSA, then purified by IP. The PKM2 enzyme activity was 
measured and normalized against protein level. Mean values of relative enzyme activity of 
triplicate experiments with standard deviation (±SD) are presented.
(G) K305Q mutation decreases the binding affinity toward PEP. The activities of wild-type 
and mutant PKM2 were assayed with increasing concentrations of ADP or PEP as indicated. 
Error bars represent ±SD for triplicate experiments.
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Figure 2. Glucose and PCAF Regulate PKM2 Acetylation and Protein Levels
(A) High glucose increases PKM2 acetylation at K305 and decreases PKM2 protein level. 
HeLa cells were cultured with 25 mM glucose medium. The steady-state level and K305 
acetylation of endogenous PKM2 were analyzed by western blot. PKM2 protein and 
acetylation levels were normalized against β-actin.
(B) PCAF binds with PKM2. 293T cells were transfected with indicated plasmids, and 
PCAF-PKM2 association was examined by IP and western blot.
(C) PCAF increases PKM2 acetylation at K305. 293T cells were transfected with indicated 
plasmids, and PKM2 acetylation at K305 was determined by western blot.
(D) High glucose promotes the interaction between PCAF and PKM2. The indicated 
plasmids were cotransfected into 293T cells, followed by indicated glucose concentration 
treatment, and the interaction between PKM2 and PCAF was examined by 
immunoprecipitation.
(E) Knocking down PCAF decreases endogenous K305 acetylation of PKM2. siRNA oligo 
targeting PCAF was transfected into 293T cells, and the levels of endogenous PCAF, PKM2 
protein, and K305 acetylation were determined by western blot.
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(F) PCAF negatively regulates PKM2 activity. PCAF expression plasmid or siRNA oligo 
targeting PCAF was cotransfected into 293T cells with a vector expressing Flag-PKM2. 
PKM2 was immunoprecipitated and activity was assayed. The mean value of triplicate 
experiments and standard deviation are presented.
(G) PCAF decreases endogenous PKM2 protein level. PCAF plasmid was transfected into 
293T cells and endogenous PKM2 protein level was measured by western blot.
(H) TSA and NAM treatment decreases the level of wild-type PKM2 but not the 
PKM2K305Q and PKM2K305R mutants. wild-type, K305Q, and K305R mutants expressing 
stable cells were treated with or without TSA and NAM, followed by western blot to 
determine PKM2 protein levels. PKM2 protein levels were normalized against β-actin.
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Figure 3. Glucose-Induced PKM2 Degradation Requires CMA
(A) High glucose induces moderate increase of PKM2 mRNA. HeLa cells were cultured 
with the increasing concentrations of glucose. The level of PKM2 mRNA was determined by 
qPCR and normalized against GAPDH. Error bars represent ±SD for triplicate experiments.
(B) Inhibition of deacetylases does not significantly affect PKM2 mRNA level. HeLa cells 
cultured in 25 mM glucose were treated with or without NAM and TSA. The levels of 
PKM2 mRNA were determined by qPCR using GAPDH as an internal control. The level of 
PKM2 mRNA in the cells treated with or without NAT and TSA are shown. Error bars 
represent ±SD for triplicate experiments.
(C) PKM2 is not degraded by the 26S proteasome pathway. 293T cells were treated with 
proteasome inhibitor MG132, and the PKM2 protein level was analyzed by western blotting. 
PEPCK, a known proteasome substrate, was included as a control.
(D) Leupeptin accumulates K305 acetylation and PKM2 protein. 293T cells were treated 
with or without Leupeptin. The levels of total and acetylated PKM2 were determined by 
western blot. PKM2 level was normalized against β-actin.
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(E) CMA activator 6-aminonicotinamide decreases PKM2 protein levels. 293T cells were 
treated with or without 6-aminonicotinamide (6-AN), and PKM2 level was determined by 
western blot.
(F) Serum withdrawal decreases PKM2 protein. PKM2 level was determined by western blot 
after serum withdrawal as indicated in 293T cells.
(G) HSC70 knockdown accumulates PKM2. Plasmid expressing HSC70 antisense was 
transfected into 293T cells. HSC70 knockdown efficiency and PKM2 level were determined 
by western blot.
(H) LAMP2A knockdown accumulates PKM2. LAMP2A was stably knocked down in HeLa 
cells by shRNA. LAMP2A knockdown efficiency was determined by Q-PCR while PKM2 
level was determined by western blot. b-actin protein (second bottom panel) and mRNA 
(bottom panel, determined by qPCR) are shown as controls.
(I) LAMP2A knockdown blocks the glucose effect on PKM2 protein levels. HeLa cell pools 
stably expressing LAMP2A shRNA were cultured in the presence of increasing 
concentrations of glucose. PKM2 expression level was determined by western blot.
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Figure 4. PKM2 Acetylation Promotes Its Binding with HSC70 and Uptake by Lysosome
(A) Acetyl mimetic K305Q mutation increases the binding between PKM2 and HSC70. The 
plasmids were cotransfected into 293T cells as indicated, the binding between PKM2 and 
HSC70 were examined by IP-western analysis.
(B) Inhibition of deacetylases increases PKM2-HSC70 binding. The plasmids were 
cotransfected into 293T cells as indicated, followed by NAM+TSA treatment. PKM2-
HSC70 binding was determined by IP-western analysis, and the levels of total and acetylated 
PKM2 were determined by western blot (lower panels).
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(C) HSC70 reduces acetylated PKM2. The plasmids were cotransfected into 293T cells as 
indicated and followed by NAM+TSA treatment, and PKM2 acetylation at K305 was 
determined by western blot.
(D) The HCS70 preferentially interacts with K305-acetylated PKM2. HA-PKM2-transfected 
cells were immunoprecipitated with HSC70 antibody (indicated as IP). Relative acetylation 
of total cellular PKM2 (Input) and the HSC70-associated pKM2 (IP) were determined by 
western blot with indicated antibodies.
(E) Endogenous PKM2 associates with HSC70. Cell lysate from H1299 cells was 
immunoprecipated with PKM2 antibody and followed by western blot analysis as indicated.
(F) Glucose promotes the PKM2-HSC70 association. Indicated plasmids were cotransfected 
into 293T cells followed by treatment with media with different glucose concentrations. The 
binding between PKM2 and HSC70 was analyzed by IP-western.
(G) Identification of a HSC70 binding motif in PKM2. The binding between PKM2 mutants 
(generated on K305Q plasmid) and HSC70 was analyzed by IP-western.
(H) PCAF increases PKM2 acetylation and shifts it to higher molecular weight fractions. 
The indicated plasmids were cotransfected into 293T cells, and cell lysates were separated 
by gel filtration, followed by western analysis. Fraction numbers and elution of molecular 
weight markers (MW) are indicated. The acetylated PKM2 is exclusively present in the high 
molecular weight fractions.
(I) Inhibition of deacetylases promotes lysosomal uptake of PKM2. Flag-tagged wild-type or 
HSC70-binding deficient mutant PKM2 was immunopurified from 293T cells treated with 
or without TSA and NAM, and incubated with the lysosomes isolated from rat liver. 
Lysosomes were reisolated and the associated PKM2 (either inside or binding to the surface) 
was determined by western blot. The presence of protease inhibitors (cocktail) should block 
lysosomal degradation, thus such conditions should measure both PKM2 binding to 
lysosomes and uptake, whereas in the absence of cocktail this assay only measures PKM2 
binding to lysosomes.
(J) The HSC70 binding-defective PKM2-393L/394A mutant has weak lysosomal binding. 
Experiments are similar to those in (I), except PKM2 mutant was used.
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Figure 5. Accumulation of Glycolytic Intermediates and NADPH in Cells Expressing Acetylation 
Mimetic K305Q Mutant
(A) Cells expressing acetylation mimetic K305Q mutant of PKM2 accumulate higher levels 
of glycolytic intermediates. Metabolites in H1299 cells wild-type (H1299/PKM2) or K305Q 
mutant (H1299/PKM2K305Q) PKM2 were analyzed by LC-MSMS. The ratios of individual 
metabolites in H1299/PKM2 expressing over H1299/PKM2K305Q-expressing cells are 
shown from three independent samples. PKM2 knockdown efficiency and re-expression 
were determined by western blot. Error bars represent ±SD for triplicate experiments.
(B) H1299/PKM2K305Q cells accumulate NADPH. Cells used in the assay were the same as 
in (A). NADPH was measured using a NADPH kit according to the manufacturer’s protocol. 
Error bars represent ±SD for triplicate experiments.
Lv et al. Page 22













Figure 6. PKM2 K305Q Promotes Cell Proliferation and Tumor Growth
(A) The expression of PKM2 and PKM2K305Q in xenograft. Whole cell tracts were prepared 
from either original stable H1299/PKM2 and H1299/PKM2K305Q pools or xenograft tumors, 
followed by western blot.
(B) PKM2K305Q promotes cell proliferation. 3 × 104 H1299/PKM2 or H1299/PKM2K305Q 
cells were seeded in each well. Cell numbers were counted every 24 hr. Error bars represent 
±SD for triplicate experiments.
(C and D) PKM2K305Q mutant promotes xenograft tumor growth. Nude mice injected on the 
left side with H1299/PKM2K305Q cells and the right side with H1299/PKM2 cells. The 
xenograft tumors were measured over time and dissected at the endpoint and shown as 
H1299/PKM2 (upper row) and H1299/PKM2K305Q (lower row) in (C). Quantification of 
average width of tumors over time is shown in (D). Error bars represent ±SD for ten tumors.
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